Novo Nordisk AS Trading in Novo Nordisk shares by board members, executives and associated persons - Yahoo Finance
NONOF Stock | USD 111.00 0.50 0.45% |
Roughly 62% of Novo Nordisk's investor base is looking to short. The analysis of overall sentiment of trading Novo Nordisk AS pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Novo Nordisk's historical and current headlines, can help investors time the market. In addition, many technical investors use Novo Nordisk AS stock news signals to limit their universe of possible portfolio assets.
Novo Nordisk pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Novo daily returns and investor perception about the current price of Novo Nordisk AS as well as its diversification or hedging effects on your existing portfolios.
Novo |
Novo Nordisk AS Trading in Novo Nordisk shares by board members, executives and associated persons Yahoo Finance
Read at news.google.com
Novo Nordisk Fundamental Analysis
We analyze Novo Nordisk's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Novo Nordisk is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Novo Nordisk AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novo Nordisk pink sheet to make a market-neutral strategy. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics with similar companies.
Peers
Novo Nordisk Related Equities
ACLX | Arcellx | 5.73 | ||||
CMXHF | CSL | 4.66 | ||||
PROK | ProKidney Corp | 1.49 | ||||
KALV | Kalvista Pharmaceuticals | 1.07 | ||||
PCVX | Vaxcyte | 0.69 | ||||
GNTA | Genenta Science | 0.19 | ||||
CSLLY | CSL | 0.66 | ||||
NUVL | Nuvalent | 1.01 | ||||
PMVP | Pmv Pharmaceuticals | 1.88 | ||||
VRDN | Viridian Therapeutics | 1.96 | ||||
CRBU | Caribou Biosciences | 5.14 | ||||
BGNE | BeiGene | 9.69 | ||||
SLRN | ACELYRIN, INC | 16.01 |
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Valuation Check real value of public entities based on technical and fundamental data |